Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc. - Enterprise Valueverified

CTNM

Price:

$14.38

Market Cap:

$537.62M

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November...[Read more]

Industry

Biotechnology

IPO Date

2024-04-04

Stock Exchange

NASDAQ

Ticker

CTNM

The Enterprise Value as of July 2026 (TTM) for Contineum Therapeutics, Inc. (CTNM) is 524.41M

According to Contineum Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 524.41M. This represents a change of 83.87% compared to the average of 285.21M of the last 4 quarters.

Contineum Therapeutics, Inc. (CTNM) Historical Enterprise Value (quarterly & annually)

How has CTNM Enterprise Value performed in the past?

The mean historical Enterprise Value of Contineum Therapeutics, Inc. over the last ten years is 390.32M. The current 524.41M Enterprise Value has changed 13.34% with respect to the historical average. Over the past ten years (40 quarters), CTNM's Enterprise Value was at its highest in in the March 2024 quarter at 573.08M. The Enterprise Value was at its lowest in in the June 2023 quarter at 0.

Quarterly (TTM)
Annual

Average

390.32M

Median

387.29M

Minimum

249.27M

Maximum

564.68M

Contineum Therapeutics, Inc. (CTNM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Contineum Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 45.80%

Maximum Annual Enterprise Value = 564.68M

Minimum Annual Increase = -35.70%

Minimum Annual Enterprise Value = 249.27M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025249.27M-31.35%
2024363.09M-35.70%
2023564.68M45.80%
2022387.29M0.00%

Contineum Therapeutics, Inc. (CTNM) Average Enterprise Value

How has CTNM Enterprise Value performed in the past?

The current Enterprise Value of Contineum Therapeutics, Inc. (CTNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

392.34M

5-year avg

390.32M

10-year avg

390.32M

Contineum Therapeutics, Inc. (CTNM) Enterprise Value vs. Peers

How is CTNM’s Enterprise Value compared to its peers?

Contineum Therapeutics, Inc.’s Enterprise Value is greater than Mereo BioPharma Group plc (12.70M), greater than Kyverna Therapeutics, Inc. (431.38M), greater than Lexeo Therapeutics, Inc. Common Stock (274.03M), less than Silence Therapeutics plc (540.03M), greater than AC Immune S.A. (173.51M), less than Alto Neuroscience, Inc. (679.64M), greater than Aldeyra The (47.63M), greater than Capricor Therapeutics, Inc. (296.18M), greater than Candel Therapeutics, Inc. (495.70M), greater than Amarin Corporation plc (154.57M),

Build a custom stock screener for Contineum Therapeutics, Inc. (CTNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Contineum Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Contineum Therapeutics, Inc. (CTNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Contineum Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Contineum Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Contineum Therapeutics, Inc. (CTNM)?

What is the 3-year average Enterprise Value for Contineum Therapeutics, Inc. (CTNM)?

What is the 5-year average Enterprise Value for Contineum Therapeutics, Inc. (CTNM)?

How does the current Enterprise Value for Contineum Therapeutics, Inc. (CTNM) compare to its historical average?